Resilience Raises $25M to Expand Remote Oncology Patient Monitoring

by

Resilience, a healthtech company specializing in remote patient monitoring for oncology, has raised $25 million in a recent funding round. This investment will bolster the company’s efforts to expand its innovative solutions across Europe, enhancing the quality of care for cancer patients.

Key Investors and Funding Utilization
The funding round was led by Picus Capital and Red River West, with continued support from existing investors Cathay Innovation, Singular, and Seaya Ventures. The funds will be used to:

  • Expand deployment in Belgium, where Resilience is already operational in three medical centers.
  • Support the submission of a reimbursement application to the Belgian regulatory agency (INAMI) in January 2024.
  • Facilitate growth in Germany, which sees 500,000 new cancer cases annually.

Innovative Remote Monitoring Platform
Resilience has developed a remote patient monitoring platform, classified as a class IIa medical device, along with a mobile app specifically for cancer patients. This platform enables continuous monitoring and support, ensuring that patients receive timely and personalized care.

Milestone Achievement in France
In October 2023, Resilience became the first remote monitoring medical device in oncology to be reimbursed by France’s national social security system. This milestone underscores the platform’s credibility and effectiveness in improving patient outcomes.

Company Vision and Leadership
Céline Lazorthes and Jonathan Benhamou, co-founders and Co-CEOs of Resilience, emphasized their commitment to a patient-centric approach, stating:

“Since we founded Resilience, we have always upheld a holistic vision deeply focused on patients and a strong mission to ensure better care. This financing will allow us to extend the positive impacts of remote monitoring, therapeutic education, and supportive care to a greater number of patients in France and abroad.”

Future Plans
The new funding will accelerate the deployment of Resilience’s solutions both in France and internationally, aiming to enhance the scope and reach of remote oncology patient monitoring. By expanding their operations and securing regulatory approvals in new markets, Resilience is set to transform cancer care through innovative, technology-driven solutions.

With a presence in over 90 medical centers and more than 10,000 patients already benefiting from its platform, Resilience is poised to make significant strides in the global healthcare landscape, ensuring that more cancer patients receive comprehensive and continuous care.

Related Stories